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Long-term immunosuppression, including corticosteroids, is a hallmark of renal transplantation.
We describe a patient who had a failed transplant after 15 years, subsequent graft nephrectomy
and withdrawal of his immunosuppression therapy including prednisolone. Within months of
complete cessation of prednisolone, he developed hypercalcaemia and subsequent systemic
symptoms including ocular, respiratory and dermatological. A skin biopsy demonstrated non-
caseating granulomatous lesion and a diagnosis of sarcoidosis was confirmed. Re-commence-
ment with prednisolone resulted in complete resolution of clinical and biochemical features of
sarcoidosis. Sarcoidosis is unlikely to present in the immunosuppressed patient. This case
highlights that unexplained hypercalcaemia at the time of withdrawal of immunosuppression,
including corticosteroids, may be a feature of sarcoidosis.
INTRODUCTION
A hallmark of renal transplantation is the requirement for
long-term immunosuppression. Over time, this requirement
wanes, and in certain situations such as graft loss, immuno-
suppression, including oral steroids, may be stopped by the
clinician. We describe a case of sarcoidosis presenting with
hypercalcaemia following withdrawal of immunosuppression.
CASE REPORT
A 45-year-old man had established renal failure (ERF) sec-
ondary to reflux nephropathy. He was treated with renal
transplantation, which after 15 years failed and he was
re-established on haemodialysis. Owing to recurrent sepsis, he
underwent a transplant nephrectomy and following this his
long-term immunosuppression including prednisolone was
weaned and eventually withdrawn.
Interestingly, prior to complete cessation of prednisolone,
routine bone mineral chemistry revealed a hypercalcaemic
episode that resolved following discontinuation of calcium
acetate 1 g t.d.s and 1-alfacalcidol 0.25 mg daily (treatment
for secondary hyperparathyroidism) (Fig. 1A).
One month after discontinuing prednisolone, he started
feeling generally unwell. A random cortisol level excluded
hypoadrenalism. Three months after discontinuing prednisol-
one, he presented with a fever and cough, and was given anti-
biotics for a presumed chest infection. Despite this therapy, his
symptoms worsened and 2 days later he was admitted to hos-
pital. He complained of sore red eyes and his cough had wor-
sened. He was dyspnoeic with an exercise tolerance of only
10 m. He had 4 kg of unintended weight loss and appeared
cyanosed. Clinical examination demonstrated red, hard, firm
nodules on the dorsum of his hands. Ophthalmological exam-
ination revealed bilateral pterygia with inflamed conjunctiva.
Chest examination revealed fine basal crepitations. A CXR was
normal.
Serum biochemistry again revealed hypercalcaemia
(3.02 mmol/l) (Fig. 1A) and a serum ACE was 132 units/l
(reference range 8–52 units/l). Other causes of hypercalcae-
mia such as multiple myeloma and prostate cancer were con-
sidered and excluded. There was no evidence of concurrent
mycobacterial infection on CT thorax and no previous
documented infection or exposure to tuberculosis. Given the
clinical and biochemical findings, we suspected systemic sar-
coidosis and a course of oral prednisolone 20 mg daily was
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commenced. A skin biopsy of the nodular lesions confirmed
non-caseating granulomas within the subcutaneous tissue
(Fig. 1B).
Following steroid treatment, there was rapid improvement
in all symptoms including shortness of breath. Following dis-
charge, the course of prednisolone was inadvertently stopped
after only 2 weeks. The symptoms rapidly returned prompting
a further admission. Prednisolone was recommenced and the
symptoms resolved.
One year later, his symptoms have not returned. His pred-
nisolone dose has been reduced to a maintenance dose of
2 mg daily. His serum ACE levels have normalized and his
serum calcium remains within the low-normal range (Fig. 1A)
with a serum PTH level consistent with secondary hyperpara-
thyroidism due to ERF.
DISCUSSION
Sarcoidosis is a multisystem disorder of uncertain aetiology. It
typically presents with one or more of the following abnormal-
ities: bilateral hilar lymphadenopathy, pulmonary infiltrates,
skin lesions and ocular involvement. It is characterized patho-
logically by non-caseating granulomas. There is an association
with hypercalcaemia in 10–20% of cases [1, 2], but clinically
important renal disease is less common [2]. Treatment of sar-
coidosis is usually with corticosteroids. For this reason, it would
be unusual that sarcoidosis should present in the context of cor-
ticosteroid use during solid organ transplantation.
In our case, hypercalcaemia was detected before complete
cessation of prednisolone therapy following renal transplant
nephrectomy. The coincidental use of 1-alfacalcidol and
calcium-containing phosphate binders initially confounded the
aetiology of the hypercalcaemia. Subsequent symptoms of sore
eyes, myalgia, cough, mild fever following complete cessation
of prednisolone are all consistent with sarcoidosis. There had
been no previous evidence of sarcoidosis in the patient’s past
medical history, and no evidence of non-caseating granulomas
was found on histological examination of the graft following
nephrectomy. A further rise in serum calcium levels coincided
with the development of skin nodules and shortness of breath.
The persistence of hypercalcaemia following the withdrawal of
calcium supplementation should have prompted investigation.
The suppressed PTH level would have initially led to the possi-
bility of a malignant condition, which is usually clinically appar-
ent in the presence of hypercalcaemia.
In our case, the development of sarcoidosis appears to have
occurred while the patient was still on low-dose corticoster-
oids. Initial non-specific symptoms developed after corticoster-
oids were stopped. Our first consideration was hypoadrenalism,
while other considerations may have included disease recur-
rence or immune-mediated rejection in the context of steroid
withdrawal. In the setting of long-term immunosuppression,
the onset of systemic symptoms should also lead to a suspicion
of tuberculosis. Consideration of a granulomatous cause of
hypercalcaemia would have ensued once the additional symp-
toms developed. The development of de novo sarcoidosis in
this context is rare but has been previously described [3, 4].
Reactivation of known sarcoidosis has also been described
in the setting of renal transplantation. The most detailed exam-
ples of this were reviewed in a case series of 18 patients who
underwent renal transplantation with a previous diagnosis of
sarcoidosis [5]. In five patients who had recurrence, two devel-
oped renal sarcoidosis and three had extra-renal manifesta-
tions, a mean period of 13 months following transplantation.
All patients were receiving immunosuppression (including
low-dose prednisolone) at the time. Kukura et al. [6] report
the finding of non-caseating granuloma in a pregnant woman
with a renal transplant. Herrero et al. [7] describe the onset of
systemic symptoms following withdrawal of immunosuppres-
sion in a patient with a failed renal transplant. Brown et al. [4]
describe renal failure following withdrawal of prednisolone
post-renal transplant. Sarcoidosis was confirmed on renal
Figure 1: Biochemical course and histological analysis. (A) Biochemical changes since prednisolone dose tapered (1) Initial rise in serum calcium and fall in
parathyroid hormone levels leading to cessation of calcium-containing phosphate binders and 1-alfacalcidol (2) Further subsequent rise leading to the diagnosis of
sarcoidosis and treatment with prednisolone (3) leading to rapid control of hypercalcaemia and return of parathyroid hormone levels to those typical of a patient
with established renal failure with secondary hyperparathyroidism. Abrupt discontinuation of prednisolone leading to return of symptoms and hypercalcaemia—
there was rapid resolution upon restarting prednisolone (4) (B) Skin Biopsy. High power view magnification Haemotoxylin and Eosin stain, 100. Several non-
caseating granulomas composed of epitheloid cells are seen in fat.
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biopsy as the cause of this. Sarcoidosis as a cause of the initial
renal failure was made retrospectively.
The most similar case to ours is described by Quack et al. [8].
In this case, the suspicion of ‘de novo’ sarcoidosis was raised in
a case with hypercalcaemia presenting 12 weeks after cessation
of corticosteroids. There had been associated weight loss and
arthralgia. In this case, thoracic imaging demonstrated hilar and
mediastinal lymphadenopathy. A diagnosis of sarcoidosis was
supported by a raised serum ACE, soluble interleukin-2 receptor
and bronchoalveolar lavage demonstrated a lymphocytic alveol-
itis where a raised CD4/CD8 ratio was found—a ratio .3.5
being consistent with sarcoidosis.
To conclude, sarcoidosis, which may normally be con-
trolled with immunosuppression including corticosteroids, is
unlikely to manifest in the immunosuppressed patient.
However, hypercalcaemia and symptoms suggestive of a sys-
temic disease, even in the immunosuppressed and especially
when immunosuppression has been withdrawn should be
investigated without bias. In our case, the systemic features in-
cluding pulmonary symptoms, hypercalcaemia, raised serum
ACE, histological findings on skin biopsy and the response to
corticosteroids support the diagnosis of sarcoidosis. Delays in
recognizing such pathology may lead to increased co-
morbidity and distress for the patient.
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